The stratification of patients on the basis of the DPYD genotype may prevent such adverse events, through the administration of a reduced dose of the chemo-drug in patients who are carriers of pathogenic variants. A routine pre-treatment screening of deleterious DPYD polymorphisms is rarely adopted...